Eisai, Novartis Sue Aurobindo to Block Copies of Banzel Tablets

Eisai Co. and Novartis Pharma AG allege that Aurobindo Pharma Ltd.’s proposed generic versions of Banzel’s 200- and 400-milligram tablets infringe a patent for the seizure treatment, according to a federal lawsuit in New Jersey.

Novartis, a unit of Switzerland-based Novartis AG, owns the patent and Eisai holds an exclusive license to it in the US, according to a complaint filed Wednesday in the US District Court for the District of New Jersey.

Eisai and Novartis seek court orders blocking copies of Banzel’s tablets while the case continues and until the patent has expired.

The suit comes as the ...